Figure 5.

Adoptive transfer of CD8⁺CD122⁺ Tregs partially diminishes the effects of resveratrol on Hepa1-6 tumor growth. The tumor models and resveratrol treatment were described in the methods, while 1 × 10⁶ CD8⁺CD122⁺ Tregs were injected intravenously 3 days after the start of resveratrol therapy. (a) Treatment schedule for Hepa1-6 tumor model. (b) Tumor growth curves over time. Significant difference is indicated as “*” between Vehicle and Res group, “+” between Res and Res+Treg group, and “#” between Vehicle and Res+Treg group (*p < 0.05, **p < 0.01; ⁺p < 0.05, ⁺⁺p < 0.01; ^#p < 0.05, ^##p < 0.01). (c) Representative images of the tumors at the end of treatment. (d) Single-cell suspensions isolated from tumor tissue at the end of treatment were prepared, stained with anti-CD45, CD8, and CD122 antibodies and analyzed via FACS. (e) Blood, spleen and draining lymph node (LN) cells were isolated from the tumor-bearing mice. The frequencies of CD8⁺CD122⁺ Tregs (d and e) were analyzed via FACS. (f) Paraffin sections were prepared for immunohistochemical staining using anti-PCNA antibody or fluorescence staining for TUNEL. Data are shown as mean ± SD (n = 4–6 mice/group; two-tailed t-test: *p < 0.05 and **p < 0.01). One of three separate experiments is shown